No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
CN Stock MarketDetailed Quotes
603983 Guangdong Marubi Biotechnology
- 30.30
- -0.83-2.67%
Not Open Feb 17 15:00 CST
12.15BMarket Cap37.45P/E (TTM)
31.10High30.01Low18.74KlotVolume31.10Open31.13Pre Close56.92MTurnover0.47%Turnover Ratio46.83P/E (Static)401.00MShares36.8252wk High3.71P/B12.15BFloat Cap19.9252wk Low34.24Limit Up401.00MShs Float90.94Historical High28.02Limit Down3.50%Amplitude17.89Historical Low0.77Dividend TTM30.38Avg Price10.98KlotAsk2.54%Div YieldTTM100Lot Size6.86KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Marubi Biological (603983): A well-established domestic brand "Wandering New Core" revitalizes and the future looks promising.
The first stock of eye cream in China has been deeply engaged in the anti-aging field for over twenty years. The company is based on skin science and biological science research, with its main Business being the research, design, production, sales, and service of Cosmetic products, with brands including Marubi, Lianhua, and Chunji. Among them, Marubi.
Express News | Open source securities: The cosmetic industry has overall entered a structured competition era.
Marubi Biotechnology (603983): Increasing investment in the medical beauty layout for regeneration, integrating the Industry Chain for collaborative development.
Marubi has made an additional investment in Shengzhirunhe, placing great importance on the field of recyclable biomaterials. Recently, Marubi Biotech invested in Shengzhirunhe, committing a subscription amount of 0.2267 million yuan, with a shareholding ratio of 4.28%. Previously, it had already invested through its subsidiary industry fund Qingdao Maoda.
CITIC SEC: The China cosmetics industry has entered a positive growth phase, focusing on the groupization and globalization of local brands.
In the medium term, the penetration rate of makeup products and the scale enhancement of single brands will help domestic brands reach leading positions. In the long term, the accumulation of brand value and the maturity of the acquisition system will drive domestic brands toward a new journey of group development and globalization.
Express News | GF SEC raised its rating on Guangdong Wanmei Biotechnology Co., Ltd. to Buy.
Marubi Biological (603983): The symbol investment Moyang Biological's hydroxyapatite products have been certified in Mexico.
Key point: Event: The company's investment fund, Qingdao Maoda, holds a 9.6% stake in Moyang Biotech. Moyang Biotech's high-end medical beauty product 'Youfu Lan Hydroxyethyl Phosphate Calcium Microsphere Facial Filler' has received the highest risk rating from Mexico's COFEPRIS.